Impedimed Limited ( (AU:IPD) ) has provided an update.
ImpediMed Limited has released its interim financial report for the half-year ending December 31, 2024, showing a 26% increase in revenue from ordinary activities, amounting to $6.008 million. Despite the revenue growth, the company reported a net loss of $11.146 million, which marks a 15% decrease in losses compared to the previous period. The report indicates no dividends were declared or paid during this period, and the net tangible assets per ordinary security decreased from $0.03 to $0.02. This financial performance reflects the company’s ongoing efforts to improve its market position while managing operational challenges.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, focusing on developing and providing non-invasive medical devices for the assessment of fluid status and body composition. The company is known for its bioimpedance spectroscopy technology, which is used in various healthcare settings to monitor and manage conditions related to fluid management and body composition.
YTD Price Performance: -5.56%
Average Trading Volume: 33,461
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $59.12M
For an in-depth examination of IPD stock, go to TipRanks’ Stock Analysis page.